News | | More »

Active Biotech’s presentation at Solebury Trout European Biotech Investor Days 2021

Year-End Report 2020 - Active Biotech AB

Interim Reports

An Experienced Team with Extensive Knowledge in Drug Development

Management

Clinical Study in Uveitis to Start During 2021

Laquinimod

Updates on our New Direction, Clinical Strategy and Project Milestones

Capital Markets Day

Novel Treatment of the Blood Cancer Multiple Myeloma

Tasquinimod

Nasdaq Stockholm
ACTI
Annual Report 2019: EN | SV
Latest Financial Report: EN | SV

Investor Relations

We Develop New Treatments for Cancer and Inflammatory Diseases

We leverage our extensive knowledge and previously generated documentation on our assets to develop novel treatments for specialist indications with high medical need and commercial value within cancer and inflammatory eye disorders. We have a stringent focus on our projects in multiple myeloma, uveitis and in solid tumors for naptumomab in partnership with NeoTX.

Novel treatments for specialist indications

Pipeline

Disease Area
Discovery
Preclinical
Phase I
Phase II
Phase III
Partner
Cancer
Naptumomab Combination with anti-PDL1 (durvalumab) in solid tumors
Tasquinimod Multiple myeloma*
Inflammation
Laquinimod Uveitis
Study ongoing
Preclinical activities ongoing
* In an academic partnership with the Abramson Cancer Center, Philadelphia, University of Pennsylvania

Our project portfolio comprises small, orally active immunomodulatory molecules as well as antibody-based immunotherapy. We have three projects in our project portfolio, Tasquinimod, Laquinimod and Naptumomab. Read more about Active Biotechs projects »

Uveitis can Lead to Severe Eye Problems Including Blindness

Laquinimod

Multiple Myeloma a Blood Cancer with Unmet Medical Need

Tasquinimod

Presentations

Welcome and Introduction

Presented by Helén Tuvesson

Laquinimod – Treatment of Inflammatory Eye Disorders

Presented by Helena Eriksson

Tasquinimod – Treatment of Multiple Myeloma

Presented by Helén Tuvesson